Fig. 2From: Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsProgression-Free Survival. At median potential follow-up of 9.7 months, radiographic PFS for all patients with durvalumab plus olaparib (n = 17) is 16.1 monthsBack to article page